Table 2.
Primary and secondary outcomes of the global and matched population.
| Outcome | Overall population | Matched population | ||||
|---|---|---|---|---|---|---|
| Methylprednisolone (n = 124) | Usual care (n = 133) | p value | Methylprednisolone (n = 117) | Usual care (n = 88) | p value | |
| Primary outcome | ||||||
| 60-day mortality | 37/122 (30.3%) | 57 (42.8%) | 0.026 | 34/115 (29.6%) | 39/88 (44.3%) | 0.022 |
|
| ||||||
| Secondary outcomes | ||||||
| 30-day mortality | 37/122 (30.3%) | 56/133 (42.1%) | 0.034 | 34 (29%) | 38 (43.2%) | 0.031 |
| Hyperglycemia | 10 (8.0%) | 5 (3.7%) | n.s | 10 (8.5%) | 5 (5.6%) | n.s |
| ICU admission | 23 (18.5%) | 26 (19.5%) | n.s | 19 (16.2%) | 21 (23.8%) | n.s |
| In-hospital mortality | 36 (29%) | 56 (42.1%) | 0,02 | 33 (28.2%) | 38 (43.2%) | 0.019 |
| LOS (days) | 8 (10) | 12 (13) | 8 (11) | 12 (12) | n.s | |
| Mechanical ventilation | 19 (15.3%) | 25 (18.7%) | n.s | 16 (13.6%) | 21 (23.8%) | n.s |
| Nosocomial infection | 29 (23.4%) | 32 (24%) | n.s | 26 (22.2%) | 25 (28.4%) | n.s |
Data are shown as the median (IQR) or n (%).ICU: intensive care unit; LOS: length of stay; n.s: not significant.